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Elevated tissue plasminogen activator in patients
with screening-detected abdominal aortic
aneurysm
Anders Wanhainen, MD, PhD,a Torbjörn K. Nilsson, MD, PhD,b David Bergqvist, MD, PhD,a Kurt
Boman, MD, PhD,c,d and Martin Björck, MD, PhD,a Uppsala, Sweden
Objective: A population-based case-control study with historical and current data was conducted in a population with a
high prevalence of disease to explore the hypothesis that the fibrinolytic system may be involved in the early pathogenesis
of abdominal aortic aneurysm (AAA).
Methods: Forty-two patients found to have AAA at population-based screening were compared with 100 controls matched
for age and sex. Mass concentration of tissue plasminogen activator (tPA mass) and tissue plasminogen activator/
plasminogen activator inhibitor-1 complex (tPA/PAI-1 complex mass) were analyzed in blood samples obtained at the
screening (current), and in blood samples obtained from a study conducted 12 years previously on the same population
(historical).
Results: Current tPA mass levels were significantly higher in AAA patients compared with controls (13.6 vs 11.4 g/L,
P .016). A similar trend was observed in historical tPA mass levels (9.8 vs 8.2 g/L, P .062). Current and historical
mass concentrations of tPA/PAI complex in AAA patients were similar to those in controls. Current tPA mass levels
retained the associations with AAA in a logistic regression model after adjustment for history of atherosclerosis (odds
ratio [OR], 1.1 per g/L, P  .039) and current smoking (OR 1.1 per g/L, P  .039). When family history of AAA
was added in a logistic regression model, the OR for current tPA mass was 1.1 per g/L (P  .056) and 1.1 per g/L
(P  .070) when treated hypertension was added.
Conclusion: The finding of elevated tPA mass, in contrast to tPA/PAI-1 complex, in plasma among patients with
screening-detected AAA supports the hypothesis that the fibrinolytic system may be important in the early pathogenesis
of AAA. (J Vasc Surg 2007;45:1109-13.)
Clinical Relevance: Early detection by screening and repair is the only option to reduce mortality from abdominal aortic
aneurysm (AAA) in the population. As a consequence, AAA screening programs have been launched in many countries.
Most AAAs detected by screening are small, however, and the current treatment of these is limited to watchful waiting.
Other therapeutic or preventive strategies are needed, necessitating a profound knowledge of the pathogenesis of AAA.One of the most important features of arterial wall in
aneurysmal disease is the degradation of the connective
tissue,1 and an increased proteolytic activity has been dem-
onstrated in the wall of abdominal aortic aneurysm
(AAA).2-4 The fibrinolytic system is a proteolytic enzymatic
system involved not only in the dissolution of fibrin in
blood vessels but also in the remodeling of the extracellular
matrix (ECM).5 Fibrinolysis is initiated by plasmin, which
plays an important role in the degradation of ECM by
directly digesting matrix proteins and by activating proteo-
lytic matrix metalloproteinases (MMP).6-8 Studies have
found elevated levels of plasmin in AAA tissue compared
with controls9 and demonstrated a correlation between
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small AAA,10 suggesting plasmin to be important in the
pathogenesis of aneurysm formation and progression.
Plasmin is regulated by tissue plasminogen activator
(tPA), urokinase-type plasminogen activator, and plasmin-
ogen activator inhibitor-1 (PAI-1). In the presence of
fibrin, tPA converts the proenzyme plasminogen within the
thrombus into plasmin, its active form.11,12 PAI-1 regu-
lates plasminogen activation by inhibiting free tPA and
forming an enzymatically inactive tPA/PAI-1 complex,
which results in a loss of plasminogen activation potential
and thereby a decreased level of proteolytic and fibrinolytic
activity.13 Fig 1 displays an overview of the fibrinolytic
system.
We previously reported the hitherto highest prevalence
of AAA in a general population.14 In this population, we
found that some traditional risk factors for atherosclerosis
were associated with AAA, but others were not, indicating
complex etiologic mechanisms.15 One of these may be the
interaction between the fibrinolytic system and the patho-
genesis of AAA. In this field, several scientific questions
remain to be answered, such as the temporal associations
between different components of the fibrinolytic system
and the development of AAA.
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population with a high prevalence of disease and with
current as well as historical blood samples, the hypothesis
that the fibrinolytic system may be involved in the patho-
genesis of AAA.
PATIENTS AND METHODS
Between 1984 and 1994, all 60-year-old men and
women living in the northern Sweden municipality of
Norsjö were invited to a health survey at their local health
center. As part the Västerbotten Intervention Program
(VIP), they donated blood to be stored at the Northern
Sweden Medical Research Bank.16 In 1999, all men and
women between 65 and 75 years of age and living in Norsjö
were invited to a health examination that included an
ultrasonography measurement of the abdominal aortic di-
ameter and a questionnaire on medical history. Fasting
blood samples were also drawn and stored. Of 555 invited,
504 subjects (91%) participated, consisting of 248 men and
256 women with a median age of 70 years.
In a previous report on traditional risk factors for
atherosclerosis in the same population,15 an AAA was de-
fined as a mean diameter30mmby both ultrasonography
(US) and computed tomography (CT); that is, US diame-
ter  CT diameter/2. However, because few previous
investigations have used CT measurements to define the
disease, comparisons with other investigations were im-
peded. In the present study, we decided to use a more
accepted definition, where an AAA was defined as a maxi-
mum infrarenal aortic diameter 30 mm by means of US
alone.14 This change in definition was made before blood
was retrieved from the blood bank.
The present study was designed as a case–control
study. Frozen plasma samples were retrieved for the analysis
of historical data for all AAA cases and controls who were
identified in the 1999 AAA screening study and who had
participated in the VIP study between 1984 and 1994.
Thus, two sets of data were used in the comparison between
AAA cases and controls: (1) from the VIP study when the
Fig 1. Overview of the fibrinolytic system. tPA, Tissue plasmin-
ogen activator; uPA, urokinase-type plasminogen activator;
PAI-1, plasminogen activator inhibitor-1.participants were at the age of 60 years (historical data), and(2) from the AAA screening when the same subjects were
between 65 and 75 years old (current data). The mean time
between assessments of historical and current data was 11.6
years (median, 12 years). The study design is displayed in
Fig 2. All participants gave their informed consent, and the
study was approved by the Ethics Committee of Umeå
University.
Venous blood was taken in ethylenediaminetetraacetic
acid (EDTA) tubes. The plasma samples were snap-frozen
within 1 hour to 20°C and stored at 80°C within a
week. All EDTA plasma analyses were thawed and analyzed
simultaneously at the same occasion. The tPA and tPA/
PAI-1 complex mass concentrations were measured with
enzyme linked immunosorbent assay (ELISA) kits (TintEl-
ize tPA and TintElize tPA/PAI-1 complex, respectively;
Biopool AB, Umeå, Sweden). The coefficients of variation
of these two assays were about 10%.
History of disease and smoking were assessed at the
AAA screening in 1999. Subjects were classified as current
smokers, former smokers, or nonsmokers. History of ath-
erosclerotic disease was defined as any combination of
self-reported coronary heart disease, cerebrovascular dis-
ease, or peripheral artery occlusive disease. Family history of
AAA was defined as having a first degree relative (ie, par-
ents, siblings, or offspring) with a known AAA.
The independent samples t test was used for compari-
son between cases and controls. Bivariate logistic regression
models were used to estimate the odds ratio (OR) for
hemostatic factors in relation to AAA after adjustment for
history of atherosclerosis, current smoking, family history
of AAA, serum creatinine level, and treated hypertension,
with “AAA” or “no AAA,” as a dichotomous dependent
variable. Statistical evaluations of the data and random
selection of controls from different groups matched for sex
and age were done with SPSS 14.0 software (SPSS, Chi-
1984 1989 1994 1999 
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Current data
tPA-PAI complex 
tPA mass 
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Fig 2. Overview of the study design. VIP,Västerbotten Interven-
tion Program; tPA-PAI; tissue plasminogen activator; PAI, plas-
minogen activator inhibitor; AAA, abdominal aortic aneurysm.cago, Ill).
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The screening identified AAAs (n  42) in 35 men
(83%) and seven women (mean age, 71.4 years). From the
AAA screening study population, 100 controls matched for
age and sex were assigned. The mean aortic diameter was
38mm (95% confidence interval [CI], 34 to 42mm; range,
30 to 81mm) in the AAA group and 24mm (95%CI, 23 to
25 mm; range, 17 to 29 mm) in the control group. Table I
summarizes baseline characteristics of the study popula-
tion.
Current tPA mass levels were significantly higher
among AAA patients compared with controls (13.6 vs 11.4
g/L, P  .016; Table II). The difference observed in
historical tPA mass levels did not reach significance (9.8 vs
8.2 g/L, P  .062; Table I). Current and historical levels
of tPA/PAI-1 complex mass in AAA patients were similar
to those in controls (Table I). There was a significant
increase in tPA mass levels within the AAA group (P 
.002) and within the control group (P  .001) over time,
but no change was observed in tPA-PAI complex mass
Table I. Baseline characteristics of the study population
AAA patients
(n  42)
Controls
(n  100) P
Age (mean years) 71.4 71.4 .95
Men 83% 83% .96
Aortic diameter (mean mm) 38 24 .001
Self-reported atherosclerotic
disease
43% 25% .046
Current smokers 18% 1% .001
Family history of AAA 23% 5% .002
Diabetes mellitus 10% 9% .87
Treated hypertension 45% 26% .034
Serum creatinine (mean
mol/L)
88 87 .95
AAA, Abdominal aortic aneurysm.
Table II. Laboratory variables in patients with screening-
detected AAA and controls matched for age and sex
Variable*
AAA
patients
(n  42)
Controls
(n  100) P
Historical†
tPA/PAI-1 complex
(g/L)
4.6  2.3 4.9  3.0 .622
tPA mass (g/L) 9.8  3.5 8.2  4.0 .062
Current†
tPA/PAI-1 complex
(g/L)
5.3  2.2 4.7  2.4 .128
tPA mass (g/L) 13.6  4.7 11.4  4.3 .016
AAA, Abdominal aortic aneurysm; tPA/PAI-1 complex, tissue plasminogen
activator-plasminogen activator inhibitor complex; tPA mass, tissue plas-
minogen activator mass concentration.
*Variables presented as means  standard deviation.
†Current data obtained at AAA screening (at the age of 65-75 years, average
71.4 years), and historical data 5-15 years (average 11.6 years) prior to
screening (at the age of 60 years).(Table III).Current tPA mass levels retained the associations with
AAA in a logistic regression model after adjustment for
history of atherosclerosis (OR 1.1 per g/L, P  .039),
current smoking (OR 1.1 per g/L, P  .039) and serum
creatinine levels (OR 1.1 per g/L, P  .022). The OR
was 1.1 per g/L (P  .056) when family history of AAA
was added in the model and 1.1 per g/L (P .070) when
treated hypertension was added.
DISCUSSION
The present study demonstrated a significant elevation
of tPA mass concentration in plasma in AAA patients com-
pared with controls. Although a novel finding, this obser-
vation is consistent with previous histologic studies.17-19
Reilly et al17 found high levels of tPA in aneurysmal aortas
compared with normal aortas and occlusive aortas,17
whereas Shireman et al18 found a similar threefold elevation
of tPA in aneurysmal and occlusive aortas compared with
normal aorta.18 In AAA, tPA messenger RNA was localized
to macrophage-like cells in the inflammatory infiltrate in
AAA,20 smooth muscle cells (SMCs),21 and the luminal
thrombus.19,22
Lindholt et al23 found a positive correlation between
plasma levels of tPA and the annual AAA expansion rate as
well as with serum cotinine, suggesting that smoking may
interact with this pathway.23 As reported previously,15
current smoking together with duration of smoking, rather
than pack-years, was the most important smoking variable
associated with AAA. In the present study, the elevation of
tPAmass concentration in plasma among AAA patients was
independent of current smoking, as well as of reported
history of atherosclerosis. However, self-reported data, in
particular smoking habits are, prone to recall bias.
In addition, those not reporting a history of cardiovas-
cular disease may have atherosclerosis that is not clinically
manifest. An interesting trend in the present study was the
higher tPA mass levels in blood obtained in mean 11.6
Table III. Differences between current* and historical†
variables ( data‡) in patients with screening-detected
AAA and controls matched for age and sex.
AAA patients
(n  42)
Controls
(n  100)
Data P Data P
tPA/PAI-1 complex
(ug/L)
0.3 .623 0.2 .558
tPA mass (ug/L) 3.8 .002 3.1 .001
AAA, Abdominal aortic aneurysm; tPA/PAI-1 complex, tissue plasminogen
activator-plasminogen activator inhibitor-1 complex; tPA mass, tissue plas-
minogen activator mass concentration.
*Current data obtained at AAA screening at the age of 65 to 75 years
(average, 71.4 years).
†Historical data obtained 5 to 15 years (average, 11.6 years) before screen-
ing at the age of 60 years.
‡Differences between current and historical data within each group, using
paired tests.years before screening. The fact that this trend was present
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suggests that plasmin-mediated proteolysis may be of
pathophysiologic importance in the early development of
AAA.
An elevation of PAI-1 in diseased aortas was associated
with the arteriosclerosis present in both aneurysmal and
occlusive disease.24,25 A higher concentration of tPA in
SMCs obtained from AAA compared with SMCs from
normal aorta was not followed by the corresponding up-
regulation of PAI-1, causing an imbalance favoring prote-
olysis.21 Defawe et al26 showed that two physiologic inhib-
itors of proteases, of which one was PAI-1, were expressed
to a lesser degree in AAA than in occlusive aortas, “suggest-
ing a significant role for protease inhibitors during the
divergent evolution of the initial atherosclerotic plaque
towards either aneurysmal or occlusive aortic disease.”26
Thus, the significantly higher mass concentration of tPA
among AAA patients, but the lack of an increase in tPA-PAI
complex in plasma, compared with controls matched for
age and sex observed in the present study may be explained
by a lower expression of PAI-1.
A limitation of this study is the small number of pa-
tients, making it susceptible to type II statistical error.
Large number of patients with AAA and historical blood
samples are not readily available, however. Despite the
small numbers, the significantly increased levels of tPAmass
concentration in current blood samples and the trend (P
.06) towards higher levels in the historical blood samples
that was found among patients with screening-detected
AAA compared with matched controls support the hypoth-
esis that proteolysis through an increased activity (or a
decreased inhibition) of the fibrinolytic system may be an
early event in the pathogenesis of AAA.
With multiple factors analyzed there is also a risk of
mass significance, or type I error. Only two fibrinolytic
factors were analyzed in the present study, but in a previous
study, 12 atherosclerotic risk factors were analyzed in the
same population,15 and we also analyzed antibodies against
three bacterial proteins in a report to be published. The
small number of patients studied made it impossible to
perform a multivariate analysis including all the 17 mea-
sured variables, but we tried to minimize the risk of con-
founding by performing a bivariate logistic regression for
the four strongest risk factors for AAA identified in the
previous publication.15 The associations between current
tPA mass levels and AAA was lost (P  .056) only when
family history of AAA was entered into the model.
Another limitation is that not all the components of the
fibrinolytic system were analyzed, such as urokinase-type
plasminogen activator mass concentration and PAI-1 as
well as other inhibitors, to get the whole picture of the
fibrinolytic balance over time. Some of these factors are,
however, undetectable in most plasma samples or are un-
stable, necessitating other storage medium than used in the
present study. PAI-1 is an extremely unstable molecule,
especially when measured by activity-based assays. We
therefore did not measure this variable in the study.Determination of tPA mass concentration and tPA/
PAI-1 have, however, been found to be stable both against
degradation and freeze/thaw events. Because tPA and its
complex does not bind to albumin and thus is not affected
by serum albumin levels, albumin does not need to be
measured.
Another important aspect to consider is that compo-
nents of the fibrinolytic system measured in the systemic
circulation might differ from the situation within vascular
beds of different organs.27 On January 1, 1999, the total
population of Norsjö was 4804, of whom 555 (11.6%)
were 65 to 75 years old. Unfortunately, no information was
available on the original cohort that entered the VIP study
between 1984 and 1994. It is essential to analyze and
report subjects lost to follow-up in cohort studies. The
present study is therefore not a true cohort study, although
the historical data were collected prospectively. Consider-
ing this limitation it was, however, possible to analyze
changes over time at an individual level. Plasma levels of
tPA mass concentration increased over time (ie, with age)
among both cases and controls, emphasizing the impor-
tance of the study design using controls matched for age
and sex. The age-dependency of tPA was described previ-
ously.28
CONCLUSIONS
To our knowledge, the present study has demonstrated
for the first time a significant and independent elevation of
tPA mass concentration, in contrast to tPA/PAI-1 com-
plex, in plasma among AAA patients compared with con-
trols. This finding supports the hypothesis that the fibrino-
lytic system may be important in the development of AAA.
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